Clinical trial
Rivastigmine Capsules in Patients With Probable Vascular Dementia
NCT00130338 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00130338 |
|---|---|
| Title | Rivastigmine Capsules in Patients With Probable Vascular Dementia |
| Official title | An Open-label Extension to Evaluate the Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Vascular Dementia |
| Intervention type | Drug |
| Interventions | Rivastigmine |
| Enrollment | 521 |
| Start date | Feb 1, 2002 |
| Primary completion | May 1, 2006 |
| Completion | May 1, 2006 |
| First posted | Aug 15, 2005 |
| Last update posted | Mar 28, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: